174 related articles for article (PubMed ID: 1984794)
21. Evaluation of a CD25-specific immunotoxin for prevention of graft-versus-host disease after unrelated marrow transplantation.
Martin PJ; Pei J; Gooley T; Anasetti C; Appelbaum FR; Deeg J; Hansen JA; Nash RA; Petersdorf EW; Storb R; Ghetie V; Schindler J; Vitetta ES
Biol Blood Marrow Transplant; 2004 Aug; 10(8):552-60. PubMed ID: 15282533
[TBL] [Abstract][Full Text] [Related]
22. In vivo blockade of CD28/CTLA4: B7/BB1 interaction with CTLA4-Ig reduces lethal murine graft-versus-host disease across the major histocompatibility complex barrier in mice.
Blazar BR; Taylor PA; Linsley PS; Vallera DA
Blood; 1994 Jun; 83(12):3815-25. PubMed ID: 7515723
[TBL] [Abstract][Full Text] [Related]
23. T cell depletion with anti-CD5 immunotoxin in histocompatible bone marrow transplantation. The correlation between residual CD5 negative T cells and subsequent graft-versus-host disease.
Filipovich AH; Vallera D; McGlave P; Polich D; Gajl-Peczalska K; Haake R; Lasky L; Blazar B; Ramsay NK; Kersey J
Transplantation; 1990 Sep; 50(3):410-5. PubMed ID: 1698319
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of an anti-CD7-ricin A chain immunoconjugate in a novel murine model of human T-cell leukemia.
Fishwild DM; Aberle S; Bernhard SL; Kung AH
Cancer Res; 1992 Jun; 52(11):3056-62. PubMed ID: 1375534
[TBL] [Abstract][Full Text] [Related]
25. Nonmitogenic anti-CD3F(ab')2 fragments inhibit lethal murine graft-versus-host disease induced across the major histocompatibility barrier.
Blazar BR; Taylor PA; Snover DC; Bluestone JA; Vallera DA
J Immunol; 1993 Jan; 150(1):265-77. PubMed ID: 8417127
[TBL] [Abstract][Full Text] [Related]
26. Amelioration of acute graft-versus-host disease and re-establishment of tolerance by short-term treatment with an anti-TCR antibody.
Maeda T; Eto M; Lin T; Nishimura Y; Kong YY; Nomoto K; Nomoto K
J Immunol; 1994 Nov; 153(9):4311-20. PubMed ID: 7930630
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of anti-CD5 ricin A chain immunoconjugate for prevention of acute graft-vs.-host disease after HLA-identical marrow transplantation.
Przepiorka D; LeMaistre CF; Huh YO; Luna M; Saria EA; Brown CT; Champlin RE
Ther Immunol; 1994 Apr; 1(2):77-82. PubMed ID: 7584486
[TBL] [Abstract][Full Text] [Related]
28. Lethal murine graft-versus-host disease induced by donor gamma/delta expressing T cells with specificity for host nonclassical major histocompatibility complex class Ib antigens.
Blazar BR; Taylor PA; Panoskaltsis-Mortari A; Barrett TA; Bluestone JA; Vallera DA
Blood; 1996 Jan; 87(2):827-37. PubMed ID: 8555509
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of a CD5-specific immunotoxin for treatment of acute graft-versus-host disease after allogeneic marrow transplantation.
Martin PJ; Nelson BJ; Appelbaum FR; Anasetti C; Deeg HJ; Hansen JA; McDonald GB; Nash RA; Sullivan KM; Witherspoon RP; Scannon PJ; Friedmann N; Storb R
Blood; 1996 Aug; 88(3):824-30. PubMed ID: 8704237
[TBL] [Abstract][Full Text] [Related]
30. Selective elimination of alloreactive donor T cells attenuates graft-versus-host disease and enhances T-cell reconstitution.
Gendelman M; Yassai M; Tivol E; Krueger A; Gorski J; Drobyski WR
Biol Blood Marrow Transplant; 2003 Dec; 9(12):742-52. PubMed ID: 14677113
[TBL] [Abstract][Full Text] [Related]
31. Successful treatment of human acute T-cell leukemia in SCID mice using the anti-CD7-deglycosylated ricin A-chain immunotoxin DA7.
Jansen B; Vallera DA; Jaszcz WB; Nguyen D; Kersey JH
Cancer Res; 1992 Mar; 52(5):1314-21. PubMed ID: 1371092
[TBL] [Abstract][Full Text] [Related]
32. Cyclosporine-induced syngeneic graft-vs-host disease: prevention of autoaggression by treatment with monoclonal antibodies to T lymphocyte cell surface determinants and to MHC class II antigens.
Hess AD; Horwitz LR; Laulis MK; Fuchs E
Clin Immunol Immunopathol; 1993 Dec; 69(3):341-50. PubMed ID: 7694818
[TBL] [Abstract][Full Text] [Related]
33. Impact of pretransplant conditioning and donor T cells on chimerism, graft-versus-host disease, graft-versus-leukemia reactivity, and tolerance after bone marrow transplantation.
Truitt RL; Atasoylu AA
Blood; 1991 Jun; 77(11):2515-23. PubMed ID: 2039833
[TBL] [Abstract][Full Text] [Related]
34. Graft-facilitating doses of ex vivo activated gammadelta T cells do not cause lethal murine graft-vs.-host disease.
Drobyski WR; Majewski D; Hanson G
Biol Blood Marrow Transplant; 1999; 5(4):222-30. PubMed ID: 10465102
[TBL] [Abstract][Full Text] [Related]
35. Bone marrow transplantation across major histocompatibility barriers. V. Protection of mice from lethal graft-vs.-host disease by pretreatment of donor cells with monoclonal anti-Thy-1.2 coupled to the toxin ricin.
Vallera DA; Youle RJ; Neville DM; Kersey JH
J Exp Med; 1982 Mar; 155(3):949-54. PubMed ID: 6120991
[TBL] [Abstract][Full Text] [Related]
36. A combination of anti-CD3 and anti-CD7 ricin A-immunotoxins for the in vivo treatment of acute graft versus host disease.
van Oosterhout YV; van Emst L; Schattenberg AV; Tax WJ; Ruiter DJ; Spits H; Nagengast FM; Masereeuw R; Evers S; de Witte T; Preijers FW
Blood; 2000 Jun; 95(12):3693-701. PubMed ID: 10845899
[TBL] [Abstract][Full Text] [Related]
37. Role of immunoregulatory donor T cells in suppression of graft-versus-host disease following donor leukocyte infusion therapy.
Johnson BD; Becker EE; LaBelle JL; Truitt RL
J Immunol; 1999 Dec; 163(12):6479-87. PubMed ID: 10586039
[TBL] [Abstract][Full Text] [Related]
38. A CD8 DE loop peptide analog prevents graft-versus-host disease in a multiple minor histocompatibility antigen-mismatched bone marrow transplantation model.
Choksi S; Kim JC; Whitaker-Menezes D; Murphy GF; Friedman TM; Korngold R
Biol Blood Marrow Transplant; 2004 Oct; 10(10):669-80. PubMed ID: 15389433
[TBL] [Abstract][Full Text] [Related]
39. Chloroquine treatment affects T-cell priming to minor histocompatibility antigens and graft-versus-host disease.
Schultz KR; Bader S; Paquet J; Li W
Blood; 1995 Dec; 86(11):4344-52. PubMed ID: 7492796
[TBL] [Abstract][Full Text] [Related]
40. Ex vivo anti-CD3 antibody-activated donor T cells have a reduced ability to cause lethal murine graft-versus-host disease but retain their ability to facilitate alloengraftment.
Drobyski WR; Majewski D; Ozker K; Hanson G
J Immunol; 1998 Sep; 161(5):2610-9. PubMed ID: 9725263
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]